Nabi Biopharmaceuticals (NASDAQ:NABI)
CAPS Rating:
The Company leverage its experience and knowledge in powering the human immune system to develop and market products that target serious medical conditions in the areas of transplantation, infectious disease and hematology/oncology.
RSS Headlines
Fool UK
Recs
Nic-Vax is gonna hit..they are the closet to getting it done....gsk will take most of the prfits...but this company may 5 bag...